The global Etanercept Market is witnessing steady expansion as demand for biologic therapies continues to increase across autoimmune disease treatment. The global Etanercept Market size was valued at US$ 16.86 billion in 2025 and is projected to reach US$ 23.21 billion by 2034. The market is anticipated to register a CAGR of 3.62% during the forecast period from 2026 to 2034.

UCL Discovery is UCL's open access repository, showcasing and providing access to UCL research outputs from all UCL disciplines.

YouTube video by Dr. Rob Swanda

Recombinant Human TNF Receptor–Fc Fusion Protein is a recombinant human TNF receptor II–Fc fusion protein, acting as a decoy for TNF, approved in China (NMPA No.S20233108; Code86981272000021). Designed to mimic etanercept but produced via CHO cells, it neutralizes , reducing inflammation in RA, psoriasis, and ankylosing spondylitis. Packaged as 25mg in 0.5mL prefilled syringe by 3SBio Pharma.

Recombinant Human TNF Receptor–Fc Fusion Protein is a recombinant human TNF receptor II–Fc fusion protein, acting as a decoy for TNF-α, approved in China (NMPA No. S20233108; Code 86981272000021). Designed to mimic etanercept but produced via CHO cells, it neutralizes TNF-α, reducing inflammation in RA, psoriasis, and ankylosing spondylitis. Packaged as 25 mg in 0.5 mL prefilled syringe by 3SBio Pharma. Strictly for laboratory/research use（Please consult the staff for other purposes）

We report a case of a 61-year-old immunosuppressed man with rheumatoid arthritis on etanercept and past intravenous drug use who presented with intractable hiccups, an unreported feature of cervical n...

Infliximab vs Etanercept - Infliximab and Etanercept—mechanism, indications, dosing, side effects, TB risk, and when to choose each biologic.

Glycosylation is one of the important post-translational modifications in protein drugs expressed by eukaryotic cells. It is closely related to the co…

Ensuring the quality of pharmaceutical products, particularly for complex recombinant protein drugs such as TNF receptor 2-Fc fusion proteins (TNFR2-Fc, Etanercept), poses significant public health ch...

Eine Kohortenstudie ermittelt ein höheres Risiko manischer Episoden unter Infliximab, Einzelberichte gibt es auch zu Adalimumab und Etanercept.

**Infliximab** and **Etanercept** are two landmark **biologic DMARDs** that transformed the treatment of **autoimmune and inflammatory diseases**. Both target **TNF-α (tumor necrosis factor alpha)** —a central driver of chronic inflammation—but they differ in **structure, route of administration, approved indications, and clinical behavior**. This in-depth guide explains **what infliximab and etanercept are, how they work, when to use each, dosing schedules, safety concerns, comparisons, and common mistakes** , making it ideal for **MBBS students, NEET-PG aspirants, clinicians, and informed patients**. ## What Are Anti-TNF Biologics? Anti-TNF drugs neutralize **Tumor Necrosis Factor alpha** , a key cytokine responsible for: * Synovial inflammation in arthritis * Intestinal inflammation in IBD * Skin & joint damage in psoriasis They are classified as **biologic DMARDs** , used when conventional drugs (like methotrexate) are inadequate. ## **Infliximab** ### What Is Infliximab? Infliximab is a **chimeric monoclonal antibody (mouse + human)** that binds **both soluble and membrane-bound TNF-α**. ### Approved Uses * **Rheumatoid Arthritis** (with methotrexate) * **Crohn’s Disease** * **Ulcerative Colitis** * Ankylosing spondylitis * Psoriatic arthritis * Severe plaque psoriasis ### Route & Dosing * **IV infusion** * Given at **0, 2, 6 weeks** , then **every 8 weeks** ### Key Strengths * Very effective in **IBD** * Rapid induction of remission * Strong TNF neutralization ### Limitations * Infusion reactions * Higher immunogenicity (antibody formation) * Hospital/infusion-center dependent ## **Etanercept** ### What Is Etanercept? Etanercept is a **soluble TNF receptor fusion protein** that acts as a **decoy receptor** , binding circulating TNF-α. ### Approved Uses * **Rheumatoid arthritis** * Juvenile idiopathic arthritis * Ankylosing spondylitis * Psoriatic arthritis * Plaque psoriasis **Not effective in Crohn’s or UC** ### Route & Dosing * **Subcutaneous injection** * **Once or twice weekly** ### Key Strengths * Self-administered at home * Lower risk of antibody formation * Fewer infusion-related issues ### Limitations * Ineffective in inflammatory bowel disease * Requires regular injections ## Mechanism of Action Feature| Infliximab| Etanercept ---|---|--- Drug type| Monoclonal antibody| Receptor fusion protein TNF binding| Soluble + membrane TNF| Soluble TNF only Cell apoptosis| Yes| Minimal IBD efficacy| ✅ Yes| ❌ No **Exam pearl:** Infliximab induces apoptosis of TNF-expressing T-cells → **key reason it works in Crohn’s disease**. ## Infliximab vs Etanercept: High-Yield Comparison Feature| Infliximab| Etanercept ---|---|--- Route| IV infusion| SC injection Dosing frequency| Every 8 weeks (maintenance)| Weekly / twice weekly Use in Crohn’s / UC| ✅ Yes| ❌ No Immunogenicity| Higher| Lower Infusion reactions| Common| None Convenience| Moderate| High ## Side Effects of Anti-TNF Therapy ### Common * Injection/infusion site reactions * Upper respiratory infections * Headache, fatigue ### Serious (Class Effects) * **Tuberculosis** reactivation * Opportunistic infections * Heart failure worsening * Demyelinating disease * Increased malignancy risk (rare) ## Pre-Treatment Screening Before starting **any anti-TNF agent** : 1. TB screening (Mantoux / IGRA) 2. Chest X-ray 3. Hepatitis B & C screening 4. Baseline CBC & LFTs ## Contraindications * Active infections * Latent TB (until treated) * Moderate to severe heart failure * Demyelinating disorders * Recent live vaccines ## Common Mistakes & How to Avoid Them ❌ Starting biologics without TB screening → **Always screen first** ❌ Using etanercept in Crohn’s → **Ineffective choice** ❌ Stopping methotrexate with infliximab → **↑ antibodies** ❌ Ignoring infections → **Hold drug during active infection** ** ** ## FAQs #### Are infliximab and etanercept chemotherapy? No—they are **biologic immunomodulators** , not cytotoxic drugs. #### Which is better for rheumatoid arthritis? Both are effective; **etanercept is more convenient** , infliximab is often combined with MTX. #### Why is etanercept not used in Crohn’s disease? It does not induce **T-cell apoptosis** in gut inflammation. #### Can these drugs cure autoimmune disease? No—but they can **induce remission and prevent damage**. #### Are biosimilars available? Yes—biosimilars of both drugs are widely used.

On February 17, 2026, the Court dismissed Sandoz’s Complaint against Amgen in Case No. 2:25-cv-00218 (E.D. Va.) for failure to state a claim...

On September 30, the U.S. District Court for the Eastern District of Virginia granted in part and denied in part the Motion to Dismiss filed by...